Loxo Oncology struck a deal with Bayer AG to develop and commercialize two cancer therapies worth up to $1.55 billion.

Astellas Institute for Regenerative Medicine and Universal Cells Inc. have entered into an exclusive worldwide license agreement to research, develop and commercialize a novel cell therapy for an undisclosed indication. The collaboration will utilize Universal Cells’ Universal Donor Cell technology to create cell therapy products that can be administered to any recipient without the need for Human Leukocyte Antigen matching.

Are there unintended consequences of gene editing? A paper published in Nature Methods indicates there are and that news sent share prices of CRISPR, Editas Medicine and Intellia tumbling.

Allergan plc said it would get exclusive access and the option to license up to five of Editas Medicine Inc.’s experimental gene-editing-based eye treatments under a research and development deal between the two companies.

China has taken the lead in CRISPR research as an oncology team in that country became the first to inject cells that contained edited genes using the technology.

MediGene and bluebird bio struck a collaborative deal to develop T cell receptor (TCR) immunotherapies against four targets that could be worth more than $1 billion.

Casebia Therapeutics, a joint venture between Bayer and CRISPR Therapeutics, plans to open laboratory and office space in Cambridge, Mass.

Merck KGaA expects to continue delivering market-beating sales growth, helped in part by new gene modification techniques.

TARRYTOWN, N.Y. and CAMBRIDGE, Mass., April 11, 2016 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Intellia Therapeutics, Inc. announced today a licensing and collaboration agreement to advance CRISPR/Cas gene-editing technology for in vivo therapeutic development. In addition to the discovery, development and commercialization of new therapies, the companies will focus on technology development of […]

SAN DIEGO, February 24, 2016 /PRNewswire/ — Regen BioPharma, Inc., (OTCBB: RGBP) and (PINK: RGBP) announced today completion of experiments, in collaboration with Dr. Santosh Kesari, demonstrating immunological mechanisms of its novel NR2F6 gene silencing approach.  Subsequent to these experiments, the Company has begun the process of compiling an Investigational New Drug Application (IND) with […]